Press "Enter" to skip to content

New patent for Taiho Oncology drug LONSURF

0
Copyright © DrugPatentWatch. Originally published at New patent for Taiho Oncology drug LONSURF

Annual Drug Patent Expirations for LONSURF
Annual Drug Patent Expirations for LONSURF

Lonsurf is a drug marketed by Taiho Oncology and is included in one NDA. It is available from one supplier. There are four patents protecting this drug.

This drug has sixty-six patent family members in twenty-nine countries.

The generic ingredient in LONSURF is tipiracil hydrochloride; trifluridine. One supplier is listed for this compound. Additional details are available on the tipiracil hydrochloride; trifluridine profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Taiho Oncology drug LONSURF
Online Certificate Course

Decision-Making for Generic Drug Entry & Branded Drug Lifecycle Management

  • When will key drug patents expire?
  • How can I find, evaluate, and plan for generic market entry opportunities?
  • How can I find proprietary out-of-court settlements and deal terms?
DrugPatentWatch - Make Better Decisions